NJ

Nishi Jyoti

Active Director Director DIN 10360292
DIN 10360292 First appointment Nov 2023 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Nov 2023
Shareholding value •••• Premium profile

About Nishi Jyoti

Data last updated:

Nishi Jyoti is a Director at Reaper Pharmaceuticals Private Limited (since 2023). The company operates in Pharma. Reaper Pharmaceuticals Private Limited reported revenue of ₹33,632 (FY 2024).

DIN 10360292
Primary Designation Director
Industry Pharma
First Appointment 01 Nov 2023
Oldest Company Age 3 yrs
Largest company Reaper Pharmaceuticals Private Limited · ₹33,632 (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director01 Nov 20232023₹33,632 (FY 2024)Active

Board colleagues of Nishi Jyoti

NameDINCompanyDesignation
Amar Jyoti10360296Reaper Pharmaceuticals Private LimitedDirector

Directorship timeline

Open interactive timeline →
Reaper Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Nishi Jyoti

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Nishi Jyoti

Nishi Jyoti currently holds 1 directorship: Reaper Pharmaceuticals Private Limited (Director, since 01 Nov 2023, revenue ₹33,632 (FY 2024)).

Nishi Jyoti was first appointed on 01 Nov 2023 as Director at Reaper Pharmaceuticals Private Limited.

The current boards of Nishi Jyoti's companies include Amar Jyoti (Reaper Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available